Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Ren S, Wang X, Han BH, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: liu y, liu c, liu t. J Immunother Cancer. 2024 Feb 21;12(2):e007227. doi: 10.1136/jitc-2023-007227. J Immunother Cancer. 2024. PMID: 38388167 Free PMC article. Clinical Trial.
Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study.
Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, Jiang TJ, Xu RH. Wang F, et al. Am J Cancer Res. 2020 Sep 1;10(9):3037-3046. eCollection 2020. Am J Cancer Res. 2020. PMID: 33042632 Free PMC article.
[Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].
Zhang L, Gong JF, Pan HM, Bai YX, Liu TS, Cheng Y, Chen YC, Huang JY, Xu TT, Ge FJ, Hsu WL, Shi J, Hu XC, Shen L. Zhang L, et al. Among authors: liu ts. Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Oct 18;54(5):971-980. doi: 10.19723/j.issn.1671-167X.2022.05.026. Beijing Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36241241 Free PMC article. Clinical Trial. Chinese.
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, Yin X, Ge M, Xiang X, Ying J, Huang J, Zhang YQ, Cheng Y, Huang Z, Yuan X, Han W, Yan D, Wang X, Liu P, Wang L, Zhang X, Luo S, Liu T, Shen L. Liu D, et al. Among authors: liu y, liu p, liu t. BMC Med. 2022 Oct 25;20(1):408. doi: 10.1186/s12916-022-02605-9. BMC Med. 2022. PMID: 36280870 Free PMC article. Clinical Trial.
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, Hao C, Fu D, Cheng Y, Yang J, Wang Q, Qin B, Pan H, Zhang J, Bai X, Zheng Q. Qin S, et al. Among authors: liu t. J Clin Oncol. 2023 Nov 20;41(33):5163-5173. doi: 10.1200/JCO.22.02630. Epub 2023 Aug 30. J Clin Oncol. 2023. PMID: 37647576 Free PMC article. Clinical Trial.
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L, Zhang W, Fan N, Cao P, Cheng Y, Zhu L, Luo S, Zong H, Bai Y, Zhou J, Deng Y, Ba Y, Liu T, Aili M, Yin X, Gu K, Dai G, Ying J, Shi J, Gao Y, Li W, Yu G, Xie L, Gai W, Wang Y, Meng P, Shi Y. Yang L, et al. Among authors: liu t. EBioMedicine. 2024 Feb;100:104966. doi: 10.1016/j.ebiom.2024.104966. Epub 2024 Jan 13. EBioMedicine. 2024. PMID: 38217945 Free PMC article. Clinical Trial.
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Chen M, Li L, Xia Q, Chen X, Liao Z, Wang C, Shen B, Zhou M, Zhang Q, Zhang Y, Qian L, Yuan X, Wang Z, Xue C, An X, Liu B, Gu K, Hou M, Wang X, Wang W, Li E, Zhong J, Cheng J, Shu Y, Yang N, Wang H, Yang R, Liu T, Deng T, Ma F, Liao W, Qiu W, Chen Y, Chen X, Zhang M, Xu R, Li X, Feng J, Ba Y, Shi Y. Chen M, et al. Among authors: liu b, liu t. Cancer. 2024 Apr 15;130(S8):1524-1538. doi: 10.1002/cncr.35292. Epub 2024 Mar 22. Cancer. 2024. PMID: 38515388
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: liu y, liu c, liu t. Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4. Cancer Immunol Immunother. 2024. PMID: 38727837 Free PMC article. Clinical Trial.
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors.
Li J, Xu Y, Zang A, Gao Y, Gao Q, Zhang Y, Wang D, Xu J, Yuan Y, Jiang H, Ying J, Shi C, Deng Y, Wang J, Liu T, Huang Y, Qian X, Pan Y, Cheng Y, Hu S, Wang J, Shi M, Wang K, Hu H, Shen L. Li J, et al. Among authors: liu t. Chin J Cancer Res. 2024 Jun 30;36(3):257-269. doi: 10.21147/j.issn.1000-9604.2024.03.03. Chin J Cancer Res. 2024. PMID: 38988490 Free PMC article.
36,022 results
You have reached the last available page of results. Please see the User Guide for more information.